GA-BIOLOG-ID
16.6.2021 17:20:11 CEST | Business Wire | Press release
Biolog-id LLC, a developer and service provider of connected healthcare solutions, announced today its partnership with AirMed – one of the first air medical transport programs in the US. As part of this partnership, biolog-id’s cutting-edge technology will provide digital visibility to the inventory of red blood cells and liquid plasma across 5 locations in the state of Utah, covering one of the largest geographical areas in the nation, routinely transporting patients not only from Utah, but also from Colorado, Wyoming, Nevada, Montana, and Idaho.
Biolog-id’s blood components management platform will support the inventory replenishment of the different bases, as well as the traceability and documentation of the units selected by the teams at the AirMed bases.
“We are pleased to cooperate with the biolog-id team on the deployment of this technology across our operation,” said Cory Cox, AirMed Outreach Coordinator & Flight Paramedic at AirMed. “We are committed to delivering the highest quality of care to our patients and strive for excellence in every aspect of our profession. The cooperation with biolog-id perfectly aligns with this mission by ensuring the availability of some of the most critical life-saving tools we have at our disposal.”
“Cooperating with an inspiring organization like AirMed is a natural expansion of our current customer base of community donor center and hospital blood banks,” said Troy L. Hilsenroth, CEO biolog-id LLC. “As a former firefighter I am particularly excited about our technology supporting the important mission of the courageous men and women at AirMed.”
The biolog-id technology is compatible across multiple systems, software, and hardware. That flexibility of the biolog-id platform, coupled with a customer-centric innovation focus, facilitates the development of dedicated tools that address the changing conditions in the industry. With an expanding customer base in the US and worldwide, this combination drives the ability to efficiently configure biolog-id’s solution. While addressing the unique needs of both donor centers and hospital blood banks, this further enables our ability to effectively scale.
About biolog-id
Biolog-id develops and implements innovative solutions, that digitally transform routine processes into actionable data supporting better operational and strategic decisions for sensitive therapeutic products: blood products (red blood cells, platelets, plasma), chemotherapies, parenteral nutrition.
The information generated by biolog-id solutions is available to Healthcare Professionals at any time, enhancing their processes efficiency, work conditions and ultimately the safety of the therapeutics administered to patients.
Biolog-id’s patented platform is utilized in North America, Europe, Middle East, India, and Asia Pacific. Biolog-id is owned by its founder, managers, and the Xerys Funds. Xerys Gestion is a French investment company primarily positioned on trending sectors that include healthcare & Life Sciences, renewable energy/GreenTech and new digital technologies.
Company URL: www.biolog-id.com
About ARUP Laboratories
ARUP Laboratories is a national nonprofit and academic reference laboratory at the forefront of diagnostic medicine. We are a CAP-, ISO 15189-, and CLIA-certified diagnostic lab with more than 35 years of experience supporting clients through unparalleled quality and service. Our forward-thinking community of academic experts and consultants are here to empower our clients with the most current industry knowledge and unparalleled guidance.
Company URL: https://www.aruplab.com/about
About U-Health AirMed:
AirMed was established on June 16, 1978, as the eighth air medical transport program in the nation. We fly trauma, burns, medical, pediatric, neonate, high-risk OB, and cardiac assist device patients 24 hours a day with six helicopters and two airplanes placed throughout northern Utah and Wyoming. We use the most state-of-the-art equipment available, which includes digital capnography, invasive line management, and intra-aortic balloon pumps for transport. We utilize cutting-edge airway technology including video laryngoscopy, advanced portable ventilators, and a variety of adjuncts for securing difficult or complex airways.
Company URL: https://healthcare.utah.edu/airmed/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005729/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dominican Republic Drives Modernization of Electronic Passports Under the Leadership of the Thales - MIDAS Consortium25.3.2026 23:22:00 CET | Press release
The General Directorate of Passports, together with the Presidency of the Dominican Republic, are leading the transformation of the country’s passport issuance system with a new, secure, efficient document aligned with international standards.In 2025, the Thales-MIDAS consortium was awarded the contract to develop, issue, and personalize a modern, secure, and highly reliable travel document for Dominican citizens, incorporating additional cybersecurity measures. The Presidency of the Dominican Republic, through the General Directorate of Passports, issued the country’s first electronic passport as part of its strategy to modernize and strengthen national security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324368065/en/ Passport of the Dominican Republic The new document was developed in partnership with Thales, world leader in advanced technologies for the Defense, Aerospace, Cybersecurity, and Digital sectors, and M
3D Systems Achieves Full-Scope EU MDR Certification, Accelerating European Launch of NextDent® Jetted Denture Solution Targeted for Summer 202625.3.2026 17:20:00 CET | Press release
Certification Marks Major Milestone in Strategic Dental Growth Initiative Addressing Straightening, Protection, Repair and Replacement of Teeth 3D Systems (NYSE: DDD) today announced it has received full-scope certification under the European Union Medical Device Regulation (EU MDR) 2017/745. The certification was attained on Monday, March 16, 2026. This milestone confirms that the Company’s quality system, technical documentation, and clinical evidence meet the most rigorous regulatory requirements in the medical device sector. With the MDR certificate in hand, 3D Systems will now introduce MDR-compliant product versions through a carefully coordinated, phased rollout across its dental product families and European markets. This approach ensures a smooth transition while maintaining uninterrupted product availability for customers and healthcare providers. The EU MDR certification immediately enables the introduction of innovative new materials and is a pivotal step for one of 3D Syst
Visa to Bring Privacy-Preserving Payments to Canton Network25.3.2026 17:00:00 CET | Press release
Visa is the first payments company selected to become a Super Validator on the Canton Network, where it will help banks and financial institutions bring new payment flows onchain Visa (NYSE:V), a global leader in digital payments, today announced it will join the Canton Network as the first major global payments company to serve as a Super Validator, to help extend privacy‑preserving blockchain infrastructure to banks and financial institutions around the world. Visa will be one of 40 Super Validators on Canton. That move goes straight to a core challenge for financial institutions: the same transparency that gives blockchains their appeal can clash with privacy expectations financial institutions operate under. Canton Network, a blockchain built for regulated finance, has privacy built in from the beginning, so organizations can use shared infrastructure without exposing sensitive information. As a Super Validator, Visa will help clients who choose to run and secure operations on the
ECU Worldwide Unveils XLERATE 2.0 Expansion to Bypass Asia–Europe Supply Chain Disruptions25.3.2026 14:30:00 CET | Press release
Strategic LAX gateway enables faster, predictable cargo movement through a reimagined sea–air logistics model ECU Worldwide, Allcargo Globals’ wholly-owned global subsidiary, has announced a strategic expansion of its transformative logistics solution, XLERATE 2.0, to provide a high-speed and resilient alternative to Asia-to-Europe trade lanes facing transit disruptions. Under this alternative routing, cargo is transported across the Pacific to the US West Coast, using Los Angeles (LAX) as a temporary hub. The solution leverages XLERATE 2.0’s premium, time-definite ocean services, ensuring greater transit agility and continuity. XLERATE 2.0 offers two distinct shipping solutions from China and Vietnam, providing shippers with flexibility as traditional trade arteries remain impacted by shifts in global logistics. These changes have led to reduced overall capacity and the disruption of standard sea–air services via conventional transit points. Commenting on the rollout, Simon Bajada, Re
Incyte Announces Executive Leadership Appointments25.3.2026 14:00:00 CET | Press release
Incyte (NASDAQ:INCY) today announced appointments among its executive leadership team to support the Company’s strategic focus and long-term growth plans. Pablo J. Cagnoni, M.D., has been appointed President, Incyte and Global Head of Research and Development. In this role, Dr. Cagnoni will retain responsibility for Research and Development, while also supporting enterprise-wide strategic planning and operational execution. Under Dr. Cagnoni’s scientific leadership, Incyte’s R&D progress has been notable, including advancing our mutCALR antibody, povorcitinib, CDK2, KRASG12D and TGFßR2xPD1 programs. Dr. Cagnoni has also continued to strengthen the way Incyte conducts R&D, introducing a new structure, processes and new technologies to improve productivity and keep Incyte competitive. Steven Stein, M.D., has been appointed Executive Vice President, Chief Medical Officer and Head of Late-stage Development. In this role, Dr. Stein will continue to oversee Incyte’s extensive and growing lat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom